Company Overview of GlycoRegImmune, Inc.
GlycoRegImmune, Inc., a biotech company, develops natural killer T (NKT) cells targeted therapies for liver disease, autoimmune disorders, and ischemic reperfusion injury. Its programs include NKT I cell inhibitors and NKT II cell modulators. The company is based in San Diego, California.
General Atomics Court
San Diego, CA 92121
Key Executives for GlycoRegImmune, Inc.
GlycoRegImmune, Inc. Key Developments
Similar Private Companies By Industry
|Salvona Consumer Care, LLC||United States|
|Washington Biotechnology, Inc.||United States|
|Selectus Pharmaceuticals||United States|
|Alydar Pharmaceuticals Inc.||United States|
|BioConvergence LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Cambridge, MA | PfizerPosted: May 10
- Kennebunk, ME | CorningPosted: May 24
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
To contact GlycoRegImmune, Inc., please visit glycoregimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.